Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension

Saudi Journal of Ophthalmology

Volumn 27, Issue 1, 2013, Pages 25-29

  Salman, Abdelrahman Gaber ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Malignant hypertension; Malignant hypertensive retinopathy

Indexed keywords

BEVACIZUMAB;

ADULT; ANGIOGRAPHY; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EYE PHOTOGRAPHY; FEMALE; HUMAN; MALE; MALIGNANT HYPERTENSION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA EXUDATE; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA MACULOPATHY; RETINOPATHY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84873271536     PISSN: 13194534     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjopt.2012.02.005     Document Type: Article

References (13)

1. Klein R., Klein B.E., Moss S.E. The relation of systemic hypertension to changes in the retinal vasculature: the beaver dam eye study. Trans Am Ophthalmol Soc 1997, 95:329-348.
2. Keith N.M., Wagener H.P., Kernohan J.W. The syndrome of malignant hypertension. Arch Intern Med 1928, 41:141-188.
3. Keith N.M., Wagener H.P., Barker N.W. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939, 197:332-339.
4. Richard JG. Current therapy in nephrology and hypertension. The CV Mosby Company. 1984-1985;324-333.
5. Areerial hypertension. World Health Organ Tech Rep Ser 1978, 628:7-56. World Health Organization.
6. McGregor E., Isles C.G., Jay J L., Lever A.F., Murray G.D. Retinal changes in malignant hypertension. Br Med J 1986, 63292:233-234.
7. Catto M.D. Management of Renal Hypertension 1988, MTP, Lancaster, p. 41-74.
8. Özkirş A. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema. Eye 2009, 23(3):616-620.
9. Haritoglou C., Kook D., Neubauer A., Wolf A., Priglinger S., Strauss R., et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006, 26:999-1005.
10. Wong T.Y., Klein R., Sharrett A.R., Manolio T.A., Hubbard L.D., Marino E.K., Kuller L., Burke G., Tracy R.P., Polak J.F., Gottdiener J.S., Siscovick D.S. The prevalence and risk factors of retinal microvascular abnormalities in older persons: the cardiovascular health study. Ophthalmology 2003, 110:658-666.
11. Browning A.C., Mengher L.S., Gregson R.M., Amoaku W.M. Visual outcome of malignant hypertension in young people. Arch Dis Child 2001, 85:401-403.
12. Manzano R.P., Peyman G.A., Khan P., et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006, 26:257-261.
13. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006, 26:279-284.